SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER

RHU GM-CSF 和 RHU IL4 治疗癌症的安全性和生物活性

• 批准号: 6118445
• 负责人: ROBERT Alan FIGLIN
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118445
• 关键词: antigen presenting cell; clinical research; clinical trial phase I; colony stimulating factor; cytotoxic T lymphocyte; drug screening /evaluation; human subject; human therapy evaluation; immune system; neoplasm /cancer immunotherapy; neoplastic cell; tumor antigens

The human immune system, when appropriately stimulated, has the capacity to recognize and destroy cancer cells. While many pathways of tumor killing have been identified, the most potent is that mediated by tumor-specific cytotoxic T-lymphocytes (CTL,1). The generation of these CTL requires a number of essential components including the presence of tumor antigens, specialized antigen presenting cells (APC) and tumor-reactive T cells (2). This protocol focuses on the administration of recombinant human GM-CSF and IL-4 to cancer patients as a means to expand and activate in vivo antigen-presenting dendritic cells (DC).

人体免疫系统在受到适当刺激时，具有识别和消灭癌细胞的能力。 虽然许多肿瘤杀伤途径已被确定，但最有效的是由肿瘤特异性细胞毒性 T 淋巴细胞 (CTL,1) 介导的途径。 这些 CTL 的生成需要许多基本成分，包括肿瘤抗原、特化抗原呈递细胞 (APC) 和肿瘤反应性 T 细胞 (2)。该协议的重点是向癌症患者施用重组人 GM-CSF 和 IL-4，作为扩展和激活体内抗原呈递树突状细胞 (DC) 的手段。